tert-butyl 5-hydroxy-2-(methylthio)-5,6-dihydropyrimidine-1(4H)-carboxylate | 247101-02-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: tert-butyl 5-hydroxy-2-(methylthio)-5,6-dihydropyrimidine-1(4H)-carboxylate
• 英文别名: Tert-butyl 5-hydroxy-2-(methylsulfanyl)-1,4,5,6-tetrahydropyrimidine-1-carboxylate；tert-butyl 5-hydroxy-2-methylsulfanyl-5,6-dihydro-4H-pyrimidine-1-carboxylate
• CAS: 247101-02-6
• 化学式: C₁₀H₁₈N₂O₃S
• 分子量: 246.331
• InChiKey: LUJZINAKCQXHHS-UHFFFAOYSA-N

物化性质

• 沸点：
  350.7±52.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  87.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 5-hydroxy-2-(methylthio)-5,6-dihydropyrimidine-1(4H)-carboxylate 、 3-氨基苯乙酸 以 N,N-二甲基乙酰胺 、 二氯甲烷 为溶剂， 反应 66.0h， 生成 2-[3-[(5-Hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]phenyl]acetic acid
  参考文献：
  名称：

  [EN] PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS
  [FR] COMPOSES DE PIPERIDINYLE LIANT SELECTIVEMENT LES INTEGRINES

  摘要：

  这项发明涉及选择性结合整合素受体的式(I)和(II)的哌啶基化合物，以及治疗整合素介导的疾病的方法，其中W、R2、Z和q在申请中有描述。

  公开号：

  WO2004020435A1
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 在 三乙胺 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 生成 tert-butyl 5-hydroxy-2-(methylthio)-5,6-dihydropyrimidine-1(4H)-carboxylate
  参考文献：
  名称：

  Pilot-Plant Preparation of an α_vβ₃ Integrin Antagonist. Part 2. Synthesis of N-[2-(5-Hydroxy-4,6-tetrahydropyrimidine)]-3-amino-5-hydroxybenzoic Acid

  摘要：

  Studies directed toward the process research and development of a scalable method for preparing tetrahydropyrimidine 2, a key intermediate to the (alpha(v)beta(3) integrin antagonist 1, are described. A linear approach employing 3-amino-5-hydroxybenzoic acid, methyl isothiocyanate, and 1,3-diaminopropan-2-ol as key reagents is detailed. The results of process development research, a successful pilot run, and a production campaign are explained.

  DOI：

  10.1021/op049968w

文献信息

• Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
  申请人：——

  公开号：US20040092538A1

  公开（公告）日：2004-05-13

  The present invention relates to a class of compounds represented by the Formula I 1 or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the &agr; v &bgr; 3 and/or &agr; v &bgr; 5 integrin.

  本发明涉及一类由公式I代表的化合物 1 或其药用可接受的盐，包含公式I化合物的药物组合物，以及选择性地抑制或拮抗α v β 3 和/或α v β 5 整合素的方法。
• [EN] 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES<br/>[FR] DERIVES DE 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE RENINE DANS LE TRAITEMENT DE L'HYPERTENSION, DE MALADIES CARDIOVASCULAIRES OU RENALES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2003093267A1

  公开（公告）日：2003-11-13

  The invention relates to novel 3,9-diazabicyclo[3.3.1]nonene derivatives of formula (I) and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors or renin.

  该发明涉及新型3,9-二氮杂双环[3.3.1]壬烯衍生物（I）及相关化合物，以及它们作为药物组合物中活性成分的用途。该发明还涉及相关方面，包括制备这些化合物的过程、含有这些化合物中的一个或多个的药物组合物，尤其是它们作为肾素抑制剂的用途。
• Piperidinyl compounds that selectively bind integrins
  申请人：De Corte Bart

  公开号：US20080058359A1

  公开（公告）日：2008-03-06

  The invention is directed to piperidinyl compounds that selectively bind integrin receptors and methods for treating an integrin mediated disorder.

  这项发明涉及选择性结合整合素受体的哌啶化合物以及治疗整合素介导疾病的方法。
• PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS
  申请人：De Corte Bart

  公开号：US20110092528A1

  公开（公告）日：2011-04-21

  The invention is directed to piperidinyl compounds that selectively bind integrin receptors and methods for treating an integrin mediated disorder.

  本发明涉及选择性结合整合素受体的哌啶化合物和治疗整合素介导的疾病的方法。
• 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP1501830A1

  公开（公告）日：2005-02-02